-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Descartes-08 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-08 in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-08 in Systemic Lupus Erythematosus Drug Details: Descartes-08 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Descartes-15 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-15 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-15 in Relapsed Multiple Myeloma Drug Details: Descartes-15 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Descartes-15 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-15 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-15 in Refractory Multiple Myeloma Drug Details: Descartes-15 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-11 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-11 in Relapsed Multiple Myeloma Drug Details: Descartes-11 is developing for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Descartes-11 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Descartes-11 in Refractory Multiple Myeloma Drug Details: Descartes-11 is developing for...
-
Product Insights
NewHearing Aid Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hearing Aid Devices Pipeline Market Report Overview Hearing aid devices are the electronic device that amplifies and transmits sound, used by people with impaired hearing. The hearing aid devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Adenoid Cystic Carcinoma (ACC) Drug...
-
Thematic Analysis
Personalization in Insurance – Thematic Intelligence
Personalization in Insurance Thematic Report Overview Insurance companies are recognizing the value of personalized policies to attract and retain customers. Insurers can personalize policies based on policyholder behaviors, preferences, and risk profiles, with unprecedented accuracy by leveraging AI and machine learning algorithms. Personalized policies not only provide customers with coverage that meets their specific requirements but also demonstrate an understanding of their unique circumstances, fostering trust and loyalty. The ‘Personalization in Insurance’ thematic intelligence report gives you an in-depth insight...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6035 in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6035 in Relapsing Multiple Sclerosis (RMS) Drug Details: RG-6035 is...
-
Analyst Opinions
Impact of Inflation on United Kingdom (UK) Insurance, 2023 Update
Impact of Inflation on UK Insurance Market Report Overview In 2023, UK inflation dropped from 10.4% in January to 4.0% in December. The following are some of the key highlights of the impact of inflation on the UK insurance market: UK policymakers made it their primary goal in 2023 to cut inflation. Paying monthly bills and the cost-of-living crisis are top financial concerns for UK insurance consumers. According to GlobalData, a large section of UK consumers is concerned about the...